Operates a chain of multi-specialty hospitals concentrated in Eastern and Central India, currently running 5 facilities with 719 beds. Mature hospitals include Salt Lake and Dum Dum (the latter recently restructured to ~71% occupancy), while the newer Raipur hospital is still ramping and posted an EBITDA loss of INR 13.8 crores in FY26. The network recorded FY26 revenue of INR 472.547 crores at a 19.07% EBITDA margin, with mature hospitals alone at a 23.06% EBITDA margin. ARPOB rose from INR 37,000 to INR 39,200 in FY26, and around 90% of revenue comes from cash and insurance patients. Robotic-assisted surgery is a stated differentiator, with Salt Lake crossing 800 robotic procedures in FY26. A 150-bed Jamshedpur hospital is slated for commissioning in Q4 FY27 at INR 70 lakh per bed, with a stated 1,000-bed target across the network within two years. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Hospital services. Asset-heavy, regional multi-specialty hospital chain with high fixed costs and occupancy-driven margins
| ₹ crore · consolidated | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 400 | 407 | 473 |
| EBITDA (ex other income) | 88 | 83 | 84 |
| margin % | 21.9 | 20.5 | 17.8 |
| Owners' profit | 48 | 50 | 42 |
| EPS, as reported (₹) | 5.96 | 6.08 | 5.15 |
| ROE % · ROCE % | 21.9 · 28.0 | 20.1 · 23.5 | 15.7 · 16.4 |
| Debt / equity (x) | 0.06 | 0.05 | 0.06 |
| Cash from operations | 69 | 67 | 81 |
| Capex | (19) | (50) | (42) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 106 | 102 | 101 | 107 | 119 | 120 | 126 | 126 |
| Profit before tax | 21 | 18 | 16 | 11 | 15 | 13 | 16 | 17 |
| Net profit | 15 | 12 | 13 | 8 | 11 | 9 | 15 | 13 |
| EPS (₹) | 1.81 | 1.49 | 1.57 | 0.94 | 1.29 | 1.14 | 1.78 | 1.55 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| APOLLO HOSPITALS ENTER. L | 1,27,062 | 60.8 | 12.74 | 33.5 | 20.1 | 16.6 | 19.0 | 16.2 |
| MAX HEALTHCARE INS LTD | 1,00,993 | 69.2 | 9.40 | 44.0 | 13.4 | 11.1 | 27.3 | 27.0 |
| FORTIS HEALTHCARE LTD | 67,025 | 64.0 | 6.59 | 32.9 | 10.5 | 9.7 | 17.8 | 22.0 |
| ASTER DM QUALITY CARE LTD | 39,689 | 124.0 | 8.21 | 40.4 | 8.8 | 8.5 | (11.6) |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 7 Aug 2026 · GPT Healthcare Q1FY27: PAT up 66%, EBITDA margin guide raised to 21% | investor communications | medium | — | — |
| 7 Aug 2026 · GPT Healthcare 37th AGM: All 10 resolutions passed, Rs 2.50 total dividend approved | board shareholder meetings | low | — | — |
| 6 Aug 2026 · GPT Healthcare 37th AGM held on Aug 6, 2026 via video conferencing | board shareholder meetings | low | — | — |
| 6 Aug 2026 · 37th AGM held on Aug 6, 2026; FY26 total dividend of Rs 2.50 per share declared | board shareholder meetings | medium | — | — |
| 4 Aug 2026 · GPT Healthcare shares Q1 FY27 results conference call audio recording | investor communications | medium | — | — |
| 4 Aug 2026 · GPT Healthcare publishes Q1FY27 Unaudited Results in newspapers | compliance | minimal | — | — |
| 3 Aug 2026 · GPT Healthcare Q1FY27 PAT up 66%, revenue up 18% YoY | results | high | — | — |
| 3 Aug 2026 · Investor Presentation on Q1 FY2027 Results | investor communications | medium | — | — |
| 3 Aug 2026 · GPT Healthcare Q1 FY27 PAT jumps 66% YoY to Rs 12.7 cr | results | high | — | — |
| 3 Aug 2026 · GPT Healthcare Q1 FY27 PAT up 66% YoY to Rs 12.73 crore | results | high | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| 14.3 |
| GLOBAL HEALTH LIMITED | 38,972 | 70.0 | 9.78 | 39.4 | 13.9 | 13.5 | — | 23.7 |
| NARAYANA HRUDAYALAYA LTD. | 38,213 | 46.5 | 8.42 | 25.4 | 17.8 | 9.2 | 25.0 | 18.8 |
| KRISHNA INST OF MED SCI L | 32,235 | 150.5 | 12.60 | 43.4 | 9.5 | 5.1 | 24.0 | 20.3 |
| DR AGARWALS HEALTH CARE L | 16,043 | 107.9 | 7.57 | 26.2 | 7.9 | 7.1 | — | 28.8 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 27.4 | 47.3 | 10 of 30 | 69% |
| P/B | 4.8 | 6.2 | 8 of 24 | 70% |
| ROCE | 14.2 | 10.9 | 7 of 30 | 79% |
| ROE | 15.7 | 11.8 | 7 of 24 | 74% |
| Debt / Equity | 0.1 | 0.2 | 5 of 24 | 83% |
| EBITDA margin | 20.8 | 22.0 | 16 of 24 | 35% |
| Revenue growth | 17.8 | 20.2 | 14 of 23 | 41% |
| Profit growth | 65.7 | 8.1 | 3 of 21 | 90% |
| Market cap | 1297 | 2415 | 20 of 30 | 35% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
